HK1080869A1 - Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis - Google Patents

Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis

Info

Publication number
HK1080869A1
HK1080869A1 HK06102455.8A HK06102455A HK1080869A1 HK 1080869 A1 HK1080869 A1 HK 1080869A1 HK 06102455 A HK06102455 A HK 06102455A HK 1080869 A1 HK1080869 A1 HK 1080869A1
Authority
HK
Hong Kong
Prior art keywords
angiogenesis
individual
polypeptides
inhibition
antibodies binding
Prior art date
Application number
HK06102455.8A
Other languages
English (en)
Inventor
Roy Bicknell
Steven Suchting
Lorna Mary Dyet Stewart
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32328072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1080869(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0227080A external-priority patent/GB0227080D0/en
Priority claimed from GB0321401A external-priority patent/GB0321401D0/en
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Publication of HK1080869A1 publication Critical patent/HK1080869A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK06102455.8A 2002-11-20 2006-02-23 Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis HK1080869A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0227080A GB0227080D0 (en) 2002-11-20 2002-11-20 Antibodies and uses thereof
GB0321401A GB0321401D0 (en) 2003-09-12 2003-09-12 Antibodies,polypeptides and uses thereof
PCT/GB2003/005059 WO2004046191A2 (en) 2002-11-20 2003-11-20 Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis

Publications (1)

Publication Number Publication Date
HK1080869A1 true HK1080869A1 (en) 2006-05-04

Family

ID=32328072

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06102455.8A HK1080869A1 (en) 2002-11-20 2006-02-23 Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis

Country Status (15)

Country Link
US (4) US20060099143A1 (el)
EP (1) EP1565491B1 (el)
JP (2) JP4869603B2 (el)
AT (1) ATE462727T1 (el)
AU (1) AU2003285500B8 (el)
CA (1) CA2506724C (el)
CY (1) CY1110661T1 (el)
DE (1) DE60331945D1 (el)
DK (1) DK1565491T3 (el)
HK (1) HK1080869A1 (el)
IL (2) IL168646A (el)
MX (1) MXPA05005470A (el)
PT (1) PT1565491E (el)
SI (1) SI1565491T1 (el)
WO (1) WO2004046191A2 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036771A2 (en) * 2000-11-06 2002-05-10 Cancer Research Technology Limited Imaging, diagnosis and treatment of disease
US6926081B2 (en) * 2002-02-25 2005-08-09 Halliburton Energy Services, Inc. Methods of discovering and correcting subterranean formation integrity problems during drilling
EP1572169B1 (en) * 2002-03-08 2013-07-17 Shanghai Institutes for Biological Sciences, CAS Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
EP1565491B1 (en) * 2002-11-20 2010-03-31 Cancer Research Technology Limited Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis
WO2006089209A2 (en) * 2005-02-17 2006-08-24 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
US7994130B2 (en) * 2006-12-11 2011-08-09 University Of Utah Research Foundation Compositions and methods for treating ocular pathologic angiogenesis and vascular permeability
MX2009008430A (es) 2007-02-09 2009-10-28 Genentech Inc Anticuerpos anti-robo4 y sus usos.
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
PL3023438T3 (pl) 2009-09-03 2020-07-27 Merck Sharp & Dohme Corp. Przeciwciała anty-gitr
WO2011027132A1 (en) 2009-09-03 2011-03-10 Cancer Research Technology Limited Clec14a inhibitors
EP2511365A4 (en) * 2009-10-23 2013-07-03 Rnl Bio Co Ltd METHOD FOR INDUCING MIGRATION OF ADULT STEM CELLS DERIVED FROM ADIPOSE TISSUE
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
JP2013529076A (ja) 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｆｇｆｒ２抗体
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
PL2841457T3 (pl) * 2012-04-27 2019-09-30 Daiichi Sankyo Company, Limited Przeciwciało anty-ROBO4
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
WO2022221314A1 (en) * 2021-04-16 2022-10-20 BioLegend, Inc. Compositions and methods involving severe acute respiratory syndrome coronavirus 2 receptor binding domain

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069007A (en) * 1989-06-21 2000-05-30 City Of Hope Ribozyme cleavage of HIV RNA
US5955291A (en) 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
EP0682113A3 (en) 1994-05-12 1996-12-18 Ono Pharmaceutical Co A polypeptide produced in an endothelial cell line and DNA encoding it.
US20040002591A1 (en) * 1997-09-05 2004-01-01 Human Genome Sciences, Inc. 50 human secreted proteins
CA2298852A1 (en) 1997-07-30 1999-02-11 Human Genome Sciences, Inc. 83 human secreted proteins
EP1019091A4 (en) 1997-09-05 2005-05-11 Human Genome Sciences Inc 50 SECRETED PROTEINS OF HUMAN ORIGIN
US6225118B1 (en) * 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis
PT1490386E (pt) 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
EP1068312A2 (en) 1998-04-09 2001-01-17 Genset 5' ests and encoded human proteins
AU2883600A (en) 1999-03-08 2000-09-28 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
JP2004515203A (ja) * 1999-08-12 2004-05-27 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒト腫瘍壊死因子レセプターｔｒ１６
WO2001023523A2 (en) 1999-09-30 2001-04-05 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
WO2002036771A2 (en) 2000-11-06 2002-05-10 Cancer Research Technology Limited Imaging, diagnosis and treatment of disease
EP1572169B1 (en) * 2002-03-08 2013-07-17 Shanghai Institutes for Biological Sciences, CAS Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
US20060160729A1 (en) 2002-06-27 2006-07-20 Li Dean Y Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
EP1565491B1 (en) 2002-11-20 2010-03-31 Cancer Research Technology Limited Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis

Also Published As

Publication number Publication date
US20060263369A1 (en) 2006-11-23
SI1565491T1 (sl) 2010-08-31
ATE462727T1 (de) 2010-04-15
AU2003285500A1 (en) 2004-06-15
PT1565491E (pt) 2010-07-06
DE60331945D1 (de) 2010-05-12
WO2004046191A3 (en) 2004-07-29
WO2004046191A2 (en) 2004-06-03
IL168646A (en) 2010-12-30
DK1565491T3 (da) 2010-07-19
JP2012050442A (ja) 2012-03-15
JP5336566B2 (ja) 2013-11-06
AU2003285500B8 (en) 2011-02-03
AU2003285500B2 (en) 2010-07-01
US8394381B2 (en) 2013-03-12
MXPA05005470A (es) 2005-09-08
CY1110661T1 (el) 2015-06-10
CA2506724A1 (en) 2004-06-03
EP1565491A2 (en) 2005-08-24
US20080166295A1 (en) 2008-07-10
JP4869603B2 (ja) 2012-02-08
JP2006524485A (ja) 2006-11-02
US20080019963A1 (en) 2008-01-24
CA2506724C (en) 2013-03-12
US20060099143A1 (en) 2006-05-11
IL204453A (en) 2014-02-27
EP1565491B1 (en) 2010-03-31

Similar Documents

Publication Publication Date Title
HK1080869A1 (en) Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
DE60030450D1 (de) Von MUC-1 abgeleitete Peptide
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
WO2003082919A3 (en) Ox40r binding agents
NZ607892A (en) Tfpi inhibitors and methods of use
EP1266025A4 (en) INTERNAL PROTEIN SCAFFOLDS FOR IMITATION OF ANTIBODIES AND OTHER BINDING PROTEINS
JP2009531283A5 (el)
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
DE69629181D1 (de) Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen
NO964650L (no) LAG-3 proteinopploselige polypeptidfraksjoner, fremgangsmate for fremstilling, terapeutisk preparat og anti-idiotype antistoff
WO2005025604A3 (en) Use of hmgb and hmgb fragments to decrease specific immune response
NZ593926A (en) Methods and compositions based on shiga toxin type 2 protein
SG160205A1 (en) Modified polypeptide
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
Navolotskaya et al. Synthetic β-endorphin-like peptide immunorphin binds to non-opioid receptors for β-endorphin on T lymphocytes
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
ZA917669B (en) Antagonists of human gamma interferon
DK1397380T3 (da) Multipelt antigent peptid, der udviser flere kopier af en epitop af et plaquedannende polypeptid, og fremgangmåder til anvendelse deraf
ATE386050T1 (de) Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
RS52448B (en) ANTITUMOR PHARMACEUTICAL COMPOSITION CONTAINING SERALIZIN POLYPEPTIDE FRAGMENTS
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
ATE538806T1 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
DK1095143T3 (da) Inhibitor til diagnosticering og behandling af patienter med hæmofili A

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161120